EUVIMEDEUVIMED entdecken
Open Access

Promoter hypomethylated PDZK1 acts as a tumorigenic gene in glioma by interacting with AKT1

Xing Ren, Dan Deng, Shasha Xiang, Jianbo Feng

Aging · 2024

DOI: 10.18632/aging.205750 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aging, 2024. Verfasst von Xing Ren und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Laboratory Medicine Center, The First Affiliated Hospital of University of South China, Hengyang 421001, Hunan, P.R. China. Hauptthemen laut MEDLINE: Brain Neoplasms, DNA Methylation, Glioma, Membrane Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioma is the most frequently diagnosed primary brain tumor and typically has a poor prognosis because of malignant proliferation and invasion. It is urgent to elucidate the mechanisms driving glioma tumorigenesis and develop novel treatments to address this deadly disease. Here, we first revealed that PDZK1 is expressed at high levels in gliomas. Promoter hypomethylation may cause high expression of PDZK1 in glioma. Knockdown of PDZK1 inhibits glioma cell proliferation and invasion in vitro. Mechanistically, further investigations revealed that the loss of PDZK1 expression by siRNA inhibited the activation of the AKT/mTOR signaling pathway, leading to cell cycle arrest and apoptosis. Clinically, high expression of PDZK1 predicts a poorer prognosis for glioma patients than low expression of PDZK1. Overall, our study revealed that PDZK1 acts as a novel oncogene in glioma by binding to AKT1 and maintaining the activation of the AKT/mTOR signaling pathway. Thus, PDZK1 may be a potential therapeutic target for glioma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsDNA MethylationGliomaMembrane ProteinsPromoter Regions, GeneticProto-Oncogene Proteins c-aktHumansMaleApoptosisCarcinogenesisCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticSignal TransductionTOR Serine-Threonine Kinases

Stichwörter der Autor:innen

AKT1PDZK1gliomahypomethylation

Substanzen

AKT1 protein, humanMembrane ProteinsMTOR protein, humanProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesPDZK1 protein, human

Autor:innen und Institutionen

  • Clinical Laboratory Medicine Center, The First Affiliated Hospital of University of South China, Hengyang 421001, Hunan, P.R. China.
  • Cancer Research Institute, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, Hunan, P.R. China.

Zitieren

APA

Ren, X., Deng, D., Xiang, S., & Feng, J. (2024). Promoter hypomethylated PDZK1 acts as a tumorigenic gene in glioma by interacting with AKT1. Aging. https://doi.org/10.18632/aging.205750

Vancouver

Ren X, Deng D, Xiang S, Feng J. Promoter hypomethylated PDZK1 acts as a tumorigenic gene in glioma by interacting with AKT1. Aging. 2024. doi:10.18632/aging.205750

BibTeX
@article{Ren2024,
  author = {Ren, Xing and Deng, Dan and Xiang, Shasha and Feng, Jianbo},
  title = {Promoter hypomethylated PDZK1 acts as a tumorigenic gene in glioma by interacting with AKT1},
  journal = {Aging},
  year = {2024},
  doi = {10.18632/aging.205750}
}
Kostenlos starten →